Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Cemdisiran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cemdisiran overview
Cemdisiran is under development for the treatment of complement-mediated diseases including paroxysmal nocturnal hemoglobinuria, myasthenia gravis, geographic atrophy. The drug program is a siRNA therapeutic targeting the Complement Component C5. It is developed based on GalNAc-Conjugate Delivery technology that enables subcutaneous and intravenous dose administration and enhanced stabilization chemistry (ESC)-GalNAc delivery platform.
It was under development for the treatment of atypical hemolytic uremic syndrome, IgA nephropathy, hematuria.
Alnylam Pharmaceuticals overview
Alnylam Pharmaceuticals (Alnylam) is a biopharmaceutical company, which discovers, develops, and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for acute hepatic porphyria, Amvuttra, for the treatment of ATTR amyloidosis with cardiomyopathy; and Oxlumo for primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi drugs in the areas of genetic medicines, hepatic infectious, cardio-metabolic, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in North America, Europe and Asia-Pacific. Alnylam is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Cemdisiran’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
